Cargando…

PD-L1/PD-1 Axis in Glioblastoma Multiforme

Glioblastoma (GBM) is the most popular primary central nervous system cancer and has an extremely expansive course. Aggressive tumor growth correlates with short median overall survival (OS) oscillating between 14 and 17 months. The survival rate of patients in a three-year follow up oscillates arou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Litak, Jakub, Mazurek, Marek, Grochowski, Cezary, Kamieniak, Piotr, Roliński, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862444/ https://www.ncbi.nlm.nih.gov/pubmed/31661771 http://dx.doi.org/10.3390/ijms20215347

Ejemplares similares

PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2021)

Micro RNA Molecules as Modulators of Treatment Resistance, Immune Checkpoints Controllers and Sensitive Biomarkers in Glioblastoma Multiforme
por: Mazurek, Marek, et al.
Publicado: (2020)

Recent Trends of microRNA Significance in Pediatric Population Glioblastoma and Current Knowledge of Micro RNA Function in Glioblastoma Multiforme
por: Mazurek, Marek, et al.
Publicado: (2020)

TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme—Future Perspectives
por: Litak, Jakub, et al.
Publicado: (2020)

Cerebral Small Vessel Disease
por: Litak, Jakub, et al.
Publicado: (2020)

Metformin as Potential Therapy for High-Grade Glioma
por: Mazurek, Marek, et al.
Publicado: (2020)

PD-L1/miR-155 Interplay in Pediatric High-Grade Glioma
por: Litak, Jakub, et al.
Publicado: (2022)

New Horizons for Hydroxyapatite Supported by DXA Assessment—A Preliminary Study
por: Litak, Jakub, et al.
Publicado: (2022)

Hydroxyapatite Use in Spine Surgery—Molecular and Clinical Aspect
por: Litak, Jakub, et al.
Publicado: (2022)

Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer
por: Zgodzinski, Witold, et al.
Publicado: (2018)

Comprehensive analysis of PD-L1 expression in glioblastoma multiforme
por: Heiland, Dieter Henrik, et al.
Publicado: (2017)

Biological and Clinical Aspects of Metastatic Spinal Tumors
por: Litak, Jakub, et al.
Publicado: (2022)

The Elevated Serum Level of IFN-γ in Patients with Failed Back Surgery Syndrome Remains Unchanged after Spinal Cord Stimulation
por: Kamieniak, Piotr, et al.
Publicado: (2019)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
por: Heynckes, Sabrina, et al.
Publicado: (2019)

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
por: Krutzek, Fabian, et al.
Publicado: (2022)

Regulatory Network of PD1 Signaling Is Associated with Prognosis in Glioblastoma Multiforme
por: Lopes-Ramos, Camila M., et al.
Publicado: (2021)

IFN-γ Correlations with Pain Assessment, Radiological Findings, and Clinical Intercourse in Patient after Lumbar Microdiscectomy: Preliminary Study
por: Kamieniak, Piotr, et al.
Publicado: (2020)

The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides
por: Grywalska, Ewelina, et al.
Publicado: (2017)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Functional differences between PD-1(+) and PD-1(-) CD4(+) effector T cells in healthy donors and patients with glioblastoma multiforme
por: Goods, Brittany A., et al.
Publicado: (2017)

The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters
por: Walankiewicz, Monika, et al.
Publicado: (2018)

Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme—a retrospective cohort study
por: Masood, Aetsam Bin, et al.
Publicado: (2023)

Targeting the PD-1/PD-L1 Axis in Human Vitiligo
por: Willemsen, Marcella, et al.
Publicado: (2020)

Role of the PD-1 and PD-L1 axis in COVID-19
por: R Bonam, Srinivasa, et al.
Publicado: (2022)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-1/PD-L Axis in Neuroinflammation: New Insights
por: Manenti, Susanna, et al.
Publicado: (2022)

Diagnosis and Management of Neuropathic Pain in Spine Diseases
por: Bielewicz, Joanna, et al.
Publicado: (2023)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
por: Cai, Jiajing, et al.
Publicado: (2019)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
por: Yajuk, Olga, et al.
Publicado: (2021)

Metallic Implants Used in Lumbar Interbody Fusion
por: Litak, Jakub, et al.
Publicado: (2022)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
por: Schönrich, Günther, et al.
Publicado: (2019)

Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
por: Scheffel, Thamiris Becker, et al.
Publicado: (2021)

SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis
por: Aghbash, Parisa Shiri, et al.
Publicado: (2021)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives
por: Ran, Xiongwen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1i0951im9oj9fn9mqchuindctr